Clinical Trials
6
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (83.3%)Phase 3
1 (16.7%)Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to dAMD
Phase 2
Not yet recruiting
- Conditions
- Non-Exudative (dry) Age-related Macular Degeneration (dAMD)
- Interventions
- Dietary Supplement: AREDS2 supplements
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05170048
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Phase 2
Not yet recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05106127
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Phase 3
Not yet recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05077215
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Phase 2
Withdrawn
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Registration Number
- NCT04561180
News
No news found